The pharmaceutical pipeline for atrial fibrillation

References

• Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, . Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114:119–25.
   PubMed Web of Science ®Google Scholar
• Friberg J, Buch P, Scharling H, Gadsbphioll N, Jensen GB. Rising rates of hospital admissions for atrial fibrillation. Epidemiology. 2003;14:666–72.
   PubMed Web of Science ®Google Scholar
• Bialy D, Lehmann H, Schumacher DN, Steinman RT, Meissner MD. Hospitalization for arrhythmias in the United States: importance of atrial fibrillation. J Am CollCardiol. 1992;19:41A–1.
   Google Scholar
• Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98:946–52.
   PubMed Web of Science ®Google Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983–8.
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Chen PS, Bild DE, Mascette AM, Albert CM, Alonso A, . Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop. Circulation. 2009;119:606–18.
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener HC, . Outcome parameters for trials in atrial fibrillation: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. Europace. 2007;9:1006–23.
   PubMed Web of Science ®Google Scholar
• Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, . Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol. 2010;3:32–8.
   PubMed Web of Science ®Google Scholar
• Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med. 1989; 321:406–12.
   Google Scholar
• Roden DM. Risks and benefits of antiarrhythmic therapy. N Engl J Med. 1994;331:785–91.
   Google Scholar
• Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, . Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet. 1996;348:7–12.
   PubMed Web of Science ®Google Scholar
• Pedersen OD, Bagger H, Keller N, Marchant B, Kober L, Torp-Pedersen C. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation. 2001;104:292–6.
   PubMed Web of Science ®Google Scholar
• Zimetbaum P. Amiodarone for atrial fibrillation. N Engl J Med. 2007;356:935–41.
   PubMed Web of Science ®Google Scholar
• Channer KS, Birchall A, Steeds RP, Walters SJ, Yeo WW, West JN, . A randomized placebo-controlled trial of pre-treatment and short- or long-term maintenance therapy with amiodarone supporting DC cardioversion for persistent atrial fibrillation. Eur Heart J. 2004;25:144–50.
   PubMed Web of Science ®Google Scholar
• Singh BN, Singh SN, Reda DJ, Tang XC, Lopez B, Harris CL, . Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005;352:1861–72.
   PubMed Web of Science ®Google Scholar
• Dobrev D, Nattel S. New antiarrhythmic drugs for treatment of atrial fibrillation. Lancet. 375:1212–23.
   Google Scholar
• Gautier P, Guillemare E, Djandjighian L, Marion A, Planchenault J, Bernhart C, . In vivo and in vitro characterization of the novel antiarrhythmic agent SSR149744C: electrophysiological, anti-adrenergic, and anti-angiotensin II effects. J Cardiovasc Pharmacol. 2004;44:244–57.
   PubMedGoogle Scholar
• Kathofer S, Thomas D, Karle CA. The novel antiarrhythmic drug dronedarone: comparison with amiodarone. Cardiovasc Drug Rev. 2005;23:217–30.
   PubMed Web of Science ®Google Scholar
• Morey TE, Seubert CN, Raatikainen MJ, Martynyuk AE, Druzgala P, Milner P, . Structure-activity relationships and electrophysiological effects of short-acting amiodarone homologs in guinea pig isolated heart. J Pharmacol ExpTher. 2001;297:260–6.
   PubMed Web of Science ®Google Scholar
• Fedida D, Orth PM, Chen JY, Lin S, Plouvier B, Jung G, . The mechanism of atrial antiarrhythmic action of RSD1235. J Cardiovasc Electrophysiol. 2005;16: 1227–38.
   PubMed Web of Science ®Google Scholar
• Orth PM, Hesketh JC, Mak CK, Yang Y, Lin S, Beatch GN, . RSD1235 blocks late INa and suppresses early afterdepolarizations and torsades de pointes induced by class III agents. Cardiovasc Res. 2006;70:486–96.
   PubMed Web of Science ®Google Scholar
• Antzelevitch C, Belardinelli L, Wu L, Fraser H, Zygmunt AC, Burashnikov A, . Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent. J Cardiovasc Pharmacol Ther. 2004;9 Suppl1:S65–83.
   Google Scholar
• Burashnikov A, Di Diego JM, Zygmunt AC, Belardinelli L, Antzelevitch C. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation. 2007;116:1449–57.
   PubMed Web of Science ®Google Scholar
• Carlsson L, Chartier D, Nattel S. Characterization of the in vivo and in vitro electrophysiological effects of the novel antiarrhythmic agent AZD7009 in atrial and ventricular tissue of the dog. J Cardiovasc Pharmacol. 2006;47:123–32.
   PubMed Web of Science ®Google Scholar
• Crijns HJ, Van Gelder IC, Walfridsson H, Kulakowski P, Ronaszeki A, Dedek V, . Safe and effective conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009. Heart Rhythm. 2006;3:1321–31.
   PubMed Web of Science ®Google Scholar
• Vermes E, Tardif JC, Bourassa MG, Racine N, Levesque S, White M, . Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation. 2003;107:2926–31.
   PubMed Web of Science ®Google Scholar
• Madrid AH, Escobar C, Rebollo JM, Marin I, Bernal E, Nannini S, . Angiotensin receptor blocker as adjunctive therapy for rhythm control in atrial fibrillation: results of the irbesartan-amiodarone trial. Card Electrophysiol Rev. 2003;7:243–6.
   Google Scholar
• Schneider MP, Hua TA, Bohm M, Wachtell K, Kjeldsen SE, Schmieder RE. Prevention of atrial fibrillation by renin-angiotensin system inhibition a meta-analysis. J Am Coll Cardiol. 2010;55:2299–307.
   PubMed Web of Science ®Google Scholar
• Santangeli P, Ferrante G, Pelargonio G, Dello Russo A, Casella M, Bartoletti S, . Usefulness of statins in preventing atrial fibrillation in patients with permanent pacemaker: a systematic review. Europace. 2010;12:649–54.
   Google Scholar
• Adam O, Neuberger HR, Bohm M, Laufs U. Prevention of atrial fibrillation with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Circulation. 2008;118:1285–93.
   PubMedGoogle Scholar
• Savelieva I, Camm J. Statins and polyunsaturated fatty acids for treatment of atrial fibrillation. Nat Clin Pract Cardiovasc Med. 2008;5:30–41.
   PubMedGoogle Scholar
• Sakabe M, Shiroshita-Takeshita A, Maguy A, Dumesnil C, Nigam A, Leung TK, . Omega-3 polyunsaturated fatty acids prevent atrial fibrillation associated with heart failure but not atrial tachycardia remodeling. Circulation. 2007; 116:2101–9.
   PubMed Web of Science ®Google Scholar
• Calo L, Bianconi L, Colivicchi F, Lamberti F, Loricchio ML, de Ruvo E, . N-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J Am Coll Cardiol. 2005;45:1723–8.
   PubMed Web of Science ®Google Scholar
• Galperin J, Elizari MV, Chiale PA, Molina RT, Ledesma R, Scapin AO, . Efficacy of amiodarone for the termination of chronic atrial fibrillation and maintenance of normal sinus rhythm: a prospective, multicenter, randomized, controlled, double blind trial. J Cardiovasc Pharmacol Ther. 2001;6:341–50.
   PubMedGoogle Scholar
• Kochiadakis GE, Igoumenidis NE, Marketou ME, Kaleboubas MD, Simantirakis EN, Vardas PE. Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: a comparative, placebo controlled study. Heart. 2000;84:251–7.
   PubMed Web of Science ®Google Scholar
• Zipes DP, Prystowsky EN, Heger JJ. Amiodarone: electrophysiologic actions, pharmacokinetics and clinical effects. J Am Coll Cardiol. 1984;3:1059–71.
   PubMed Web of Science ®Google Scholar
• Grossman M, Dobrev D, Kirch W. Amiodarone causes endothelium-dependent vasodilation in human hand veins in vivo. Clin Pharmacol Ther. 1998;64:302–11.
   Google Scholar
• Grossmann M, Dobrev D, Himmel HM, Kirch W. Local venous response to N-desethylamiodarone in humans. Clin Pharmacol Ther. 2000;67:22–31.
   Google Scholar
• Zimetbaum PJ. Dronedarone for atrial fibrillation—an odyssey. N Engl J Med. 2009;360:1811–3.
   PubMed Web of Science ®Google Scholar
• Center for Drug Evaluation and Research. Briefing information for the March 18, 2009 meeting of the Cardiovascular and Renal Drugs Advisory Committee [Online]. February 19, 2009. Available from: URL: http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/ucm134972.htm. (Accessed date: August 2010).
   Google Scholar
• Center for Drug Evalution and Research. Cordarone (amiodarone) prescribing information [Online]. April, 21 2009. Available from: URL: http://www.accessdata.fda.gov/drugsatfda˙docs/label/2009/018972s038s039lbl.pdf. (Accessed date: August 2010).
   Google Scholar
• Touboul P, Brugada J, Capucci A, Crijns HJ, Edvardsson N, Hohnloser SH. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J. 2003;24:1481–7.
   PubMed Web of Science ®Google Scholar
• Singh BN, Connolly SJ, Crijns HJ, Roy D, Kowey PR, Capucci A, . Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007;357:987–99.
   PubMed Web of Science ®Google Scholar
• Tschuppert Y, Buclin T, Rothuizen LE, Decosterd LA, Galleyrand J, Gaud C, . Effect of dronedarone on renal function in healthy subjects. Br J Clin Pharmacol. 2007;64:785–91.
   PubMed Web of Science ®Google Scholar
• Davy JM, Herold M, Hoglund C, Timmermans A, Alings A, Radzik D, . Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J. 2008;156:527,e1–9.
   PubMed Web of Science ®Google Scholar
• Hohnloser SH, Connolly SJ, Van Eickels M, Radzik D, Davy JM, Singh BN. Effect of dronedarone on cardiovascular outcomes: a meta-analysis of five randomized controlled trials in 6157 patients with atrial fibrillation/flutter. J Am Coll Cardiol. 2009;53:A113.
   Google Scholar
• Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, . Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360:668–78.
   PubMed Web of Science ®Google Scholar
• Le Heuzey JY, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: The DIONYSOS Study. J Cardiovasc Electrophysiol. 2010;21:597–605.
   PubMed Web of Science ®Google Scholar
• Kober L, Torp-Pedersen C, McMurray JJ, Gotzsche O, Levy S, Crijns H, . Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358:2678–87.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Crijns HJ, Torp-Pedersen C, van Eickels M, Gaudin C, Page RL, . Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Circulation. 2009;120:1174–80.
   PubMed Web of Science ®Google Scholar
• Lee KL, McNeer JF, Starmer CF, Harris PJ, Rosati RA. Clinical judgment and statistics. Lessons from a simulated randomized trial in coronary artery disease. Circulation. 1980;61:508–15.
   PubMed Web of Science ®Google Scholar
• Arya A, Silberbauer J, Teichman SL, Milner P, Sulke N, Camm AJ. A preliminary assessment of the effects of ATI-2042 in subjects with paroxysmal atrial fibrillation using implanted pacemaker methodology. Europace. 2009;11:458–64.
   PubMed Web of Science ®Google Scholar
• Ezekowitz MD, Hohnloser SH, Lubinski A, Bandman O, Canafax D, Ellis DJ, . PASCAL: a randomized doubleblind,placebo-controlled study of budiodarone (ATI-2042) in patients with paroxysmal atrial fibrillation and pacemakers with atrial fibrillation data logging capabilities [abstract]. Heart Rhythm. 2009;6:Supplement.
   Google Scholar
• Gautier P, Serre M, Cosnier-Pucheu S, Djandjighian L, Roccon A, Herbert JM, . In vivo and in vitro antiarrhythmic effects of SSR149744C in animal models of atrial fibrillation and ventricular arrhythmias. J Cardiovasc Pharmacol. 2005;45:125–35.
   Google Scholar
• Kowey PR, Aliot E, Cappucci A, Connolly SJ, Crijns H, Hohnloser SH, . Placebo-controlled,double-blind dose-ranging study of the efficacy and safety of SSR149744C in patients with recent atrial fibrillation/flutter [abstract]. Heart Rhythm. 2007;5:S72.
   Google Scholar
• Kowey PR, Aliot E, Cappucci A, Connolly SJ, Hohnloser SH, Kulakowski P, . Placebo-controlled double-blind dose ranging study of the efficacy and safety of celivarone for the prevention of ventricular arrhythmia-triggered ICD interventions [abstract]. J Am Coll Cardiol. 2008;51:A2.
   Google Scholar
• Dobrev D, Graf E, Wettwer E, Himmel HM, Hala O, Doerfel C, . Molecular basis of downregulation of G-protein-coupled inward rectifying K(+) current (I(K,ACh) in chronic human atrial fibrillation: decrease in GIRK4 mRNA correlates with reduced I(K,ACh) and muscarinic receptor-mediated shortening of action potentials. Circulation. 2001;104:2551–7.
   Google Scholar
• Voigt N, Rozmaritsa N, Trausch A, Zimniak T, Christ T, Wettwer E, . Inhibition of IK, ACh current may contribute to clinical efficacy of class I and class III antiarrhythmic drugs in patients with atrial fibrillation. Naunyn Schmiedebergs Arch Pharmacol. 381:251–9.
   Google Scholar
• Antzelevitch C, Burashnikov A. Atrial-selective sodium channel block as a novel strategy for the management of atrial fibrillation. J Electrocardiol. 2009;42:543–8.
   PubMed Web of Science ®Google Scholar
• Das S, Makino S, Melman YF, Shea MA, Goyal SB, Rosenzweig A, . Mutation in the S3 segment of KCNQ1 results in familial lone atrial fibrillation. Heart Rhythm. 2009;6:1146–53.
   PubMed Web of Science ®Google Scholar
• Harleton E, Besana A, Argenziano M, Robinson RB, Feinmark SJ. Inhibitory phosphorylation of TASK-1 is associated with atrial fibrillation. FASEB J. 2008;22: 721.3.
   Google Scholar
• Nattel S, De Blasio E, Wang WQ, Beatch GN. RSD1235: A novel antiarrhythmic agent with a unique electrophysiological profile that terminates AF in dogs. Eur Heart J. 2001;22:448.
   Google Scholar
• Comtois P, Sakabe M, Vigmond EJ, Munoz M, Texier A, Shiroshita-Takeshita A, . Mechanisms of atrial fibrillation termination by rapidly unbinding Na+ channel blockers: insights from mathematical models and experimental correlates. Am J Physiol Heart Circ Physiol. 2008;295: H1489–504.
   PubMed Web of Science ®Google Scholar
• Dorian P, Pinter A, Mangat I, Korley V, Cvitkovic SS, Beatch GN. The effect of vernakalant (RSD1235), an investigational antiarrhythmic agent, on atrial electrophysiology in humans. J Cardiovasc Pharmacol. 2007;50:35–40.
   PubMed Web of Science ®Google Scholar
• Kowey PR, Dorian P, Mitchell LB, Pratt CM, Roy D, Schwartz PJ, . Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol. 2009;2:652–9.
   PubMed Web of Science ®Google Scholar
• Mao ZL, Wheeler JJ, Clohs L, Beatch GN, Keirns J. Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors. J Clin Pharmacol. 2009;49:17–29.
   PubMed Web of Science ®Google Scholar
• Naccarelli GV, Wolbrette DL, Samii S, Banchs JE, Penny-Peterson E, Stevenson R, . Vernakalant—a promising therapy for conversion of recent-onset atrial fibrillation. Expert Opin Investig Drugs. 2008;17:805–10.
   PubMed Web of Science ®Google Scholar
• Roy D, Pratt CM, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, . Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation. 2008;117:1518–25.
   PubMed Web of Science ®Google Scholar
• Roy D, Rowe BH, Stiell IG, Coutu B, Ip JH, Phaneuf D, . A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J Am Coll Cardiol. 2004;44:2355–61.
   PubMed Web of Science ®Google Scholar
• Camm AJ. Clinical efficacy and safety of vernakalant compared with amiodarone for intravenous conversion of recent onset atrial fibrillation. Late Break Clinical Trials Session II. Presented at Heart Rhythm Society 2010 Scientific Sessions; 14 May 2010; Denver, CO, USA.
   Google Scholar
• Kowey PR, Roy D, Pratt CM, Schwartz PJ, Dorian P, Mitchell JB, . Efficacy and safety of vernakalant hydrochloride injection for the treatment of atrial fibrillation after valvular or coronary artery bypass surgery [abstract]. Circulation. 2007;114:636–37.
   Google Scholar
• Pratt CM, Roy D, Juul-Moller S, Torp-Pedersen C, Toft E, Nielsen T. Efficacy and tolerance of RSD1235 in the treatment of atrial fibrillation or atrial flutter: results of a phase III, randomized, placebo-controlled, multicenter trial [abstract]. J Am Coll Cardiol. 2006;47:10A.
   Google Scholar
• Wettwer E, Bormann S, Christ T, Dobrev D, Pourrier M, Gibson JK, . Effects of the novel antiarrhythmic agent vernakalant (RSD1235) on human atrial action potentials in chronic atrial fibrillation. Eur Heart J. 2007;28:400.
   Google Scholar
• Cheng JW. Vernakalant in the management of atrial fibrillation. Ann Pharmacother. 2008;42:533–42.
   PubMed Web of Science ®Google Scholar
• Cardiome Pharma Corp. Available from: URL: http://www.cardiome.com/VernakalantIntravenous.php. (Accessed date: August 2010).
   Google Scholar
• Keating GM. Ranolazine: a review of its use in chronic stable angina pectoris. Drugs. 2008;68:2483–503.
   PubMed Web of Science ®Google Scholar
• Zaza A, Belardinelli L, Shryock JC. Pathophysiology and pharmacology of the cardiac ‘late sodium current’. Pharmacol Ther. 2008;119:326–39.
   PubMed Web of Science ®Google Scholar
• Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Murphy SA, Budaj A, Varshavsky S, . Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA. 2007;297: 1775–83.
   PubMed Web of Science ®Google Scholar
• Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, . Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation. 2004;110:904–10.
   PubMed Web of Science ®Google Scholar
• Sossalla S, Kallmeyer B, Wagner S, Mazur M, Maurer U, Toischer K, . Altered Na(+) currents in atrial fibrillation effects of ranolazine on arrhythmias and contractility in human atrial myocardium. J Am Coll Cardiol. 2010;55: 2330–42.
   PubMed Web of Science ®Google Scholar
• Scirica BM, Morrow DA, Hod H, Murphy SA, Belardinelli L, Hedgepeth CM, . Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation. 2007; 116:1647–52.
   PubMed Web of Science ®Google Scholar
• Sicouri S, Glass A, Belardinelli L, Antzelevitch C. Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. Heart Rhythm. 2008;5:1019–26.
   PubMed Web of Science ®Google Scholar
• Murdock DK, Overton N, Kersten M, Kaliebe J, Devecchi F. The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation. Indian Pacing Electrophysiol J. 2008;8:175–81.
   PubMedGoogle Scholar
• Rivard L, Shiroshita-Takeshita A, Maltais C, Ford J, Pinnock R, Madge D, . Electrophysiological and atrial antiarrhythmic effects of a novel IKur/Kv1.5 blocker in dogs. Heart Rhythm. 2005;2:S180.
   Google Scholar
• Milnes JT, Louis L, Rogers M, Madge D, Ford J. The atrial antiarrhythmic drug XEN-D0101 selectively inhibits the human ultra-rapid delayed-rectifier potassium current (IKur) over other cardiac ion channels. Circulation. 2008;118:S342.
   Web of Science ®Google Scholar
• Duker G, Björkman JA, Linhardt G, Carlsson L. AZD—7009—a new atrial antifibrillatory compound that markedly delays atrial refractoriness in the anaesthetised dog. Heart Rhythm. 2004;1:S159.
   Google Scholar
• Goldstein RN, Khrestian C, Carlsson L, Waldo AL. Azd7009: a new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model. J Cardiovasc Electrophysiol. 2004;15: 1444–50.
   PubMed Web of Science ®Google Scholar
• Persson F, Carlsson L, Duker G, Jacobson I. Blocking characteristics of hERG, hNav1.5, and hKvLQT1/hminK after administration of the novel anti-arrhythmic compound AZD7009. J Cardiovasc Electrophysiol. 2005;16:329–41.
   PubMed Web of Science ®Google Scholar
• Astra Zeneca Clinical Trials. Available from: URL: http://www.astrazenecaclinicaltrials.com/other-drug-products/discontinued-products/AZD7009/. (Accessed date: August 2010).
   Google Scholar
• Gogelein H, Brendel J, Steinmeyer K, Strubing C, Picard N, Rampe D, . Effects of the atrial antiarrhythmic drug AVE0118 on cardiac ion channels. NaunynSchmiedebergs Arch Pharmacol. 2004;370:183–92.
   PubMed Web of Science ®Google Scholar
• Wirth KJ, Paehler T, Rosenstein B, Knobloch K, Maier T, Frenzel J, . Atrial effects of the novel K(+)-channel-blocker AVE0118 in anesthetized pigs. Cardiovasc Res. 2003;60:298–306.
   PubMed Web of Science ®Google Scholar
• Blaauw Y, Gogelein H, Tieleman RG, van Hunnik A, Schotten U, Allessie MA. ‘Early’ class III drugs for the treatment of atrial fibrillation: efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat. Circulation. 2004;110:1717–24.
   PubMed Web of Science ®Google Scholar
• Wettwer E, Hala O, Christ T, Heubach JF, Dobrev D, Knaut M, . Role of IKur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation. Circulation. 2004; 110:2299–306.
   PubMed Web of Science ®Google Scholar
• Sanofi-Aventis Website. Sanofi-Aventis R&D Portfolio. Sept 2007. Available from: URL: http://en.sanofi-aventis.com/rd/portfolio/p_rd_portfolio_ cardio.asp. (Accessed date: August 2010).
   Google Scholar
• Wirth KJ, Brendel J, Steinmeyer K, Linz DK, Rutten H, Gogelein H. In vitro and in vivo effects of the atrial selective antiarrhythmic compound AVE1231. J Cardiovasc Pharmacol. 2007;49:197–206.
   PubMed Web of Science ®Google Scholar
• Matsuda T, Takeda K, Ito M, Yamagishi R, Tamura M, Nakamura H, . Atria selective prolongation by NIP-142, an antiarrhythmic agent, of refractory period and action potential duration in guinea pig myocardium. J Pharmacol Sci. 2005;98:33–40.
   PubMed Web of Science ®Google Scholar
• Hashimoto N, Yamashita T, Fujikura N, Tsuruzoe N. NIP-141, a multiple ion channel blocker, terminates aconitine-induced atrial fibrillation and prevents the rapid pacing-induced atrial effective refractory period shortening in dogs. Europace. 2007;9:246–51.
   Google Scholar
• Ehrlich JR. Inward rectifier potassium currents as a target for atrial fibrillation therapy. J Cardiovasc Pharmacol. 2008;52:129–35.
   Google Scholar
• Fredholm BB, Abbracchio MP, Burnstock G, Dubyak GR, Harden TK, Jacobson KA, . Towards a revised nomenclature for P1 and P2 receptors. Trends Pharmacol Sci. 1997;18:79–82.
   PubMed Web of Science ®Google Scholar
• Gao ZG, Jacobson KA. Emerging adenosine receptor agonists. Expert Opin Emerg Drugs. 2007;12:479–92.
   PubMed Web of Science ®Google Scholar
• Blomstrom-Lundqvist C, Scheinman MM, Aliot EM, Alpert JS, Calkins H, Camm AJ, . ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias). Circulation. 2003;108:1871–909.
   PubMed Web of Science ®Google Scholar
• Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, . ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114:e257–354.
   PubMed Web of Science ®Google Scholar
• Snowdy S, Liang HX, Blackburn B, Lum R, Nelson M, Wang L, . A comparison of an A1 adenosine receptor agonist (CVT-510) with diltiazem for slowing of AV nodal conduction in guinea-pig. Br J Pharmacol. 1999;126: 137–46.
   PubMed Web of Science ®Google Scholar
• Tortella FC, Martin DA, Allot CP, Steel JA, Blackburn TP, Loveday BE, . Dextromethorphan attenuates post-ischemic hypoperfusion following incomplete global ischemia in the anesthetized rat. Brain Res. 1989;482: 179–83.
   Google Scholar
• Lerman BB, Ellenbogen KA, Kadish A, Platia E, Stein KM, Markowitz SM, . Electrophysiologic effects of a novel selective adenosine A1 agonist (CVT-510) on atrioventricular nodal conduction in humans. J Cardiovasc Pharmacol Ther. 2001;6:237–45.
   PubMedGoogle Scholar
• Safety Study of Tecadenoson to Treat Atrial Fibrillation. Available from: URL: http://www.clinicaltrials.gov/ct2/show/NCT00713401?term=tecadenoson&rank=1. (Accessed date: August 2010).
   Google Scholar
• Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol. 2008;1:62–73.
   PubMed Web of Science ®Google Scholar
• Verma A, Wazni OM, Marrouche NF, Martin DO, Kilicaslan F, Minor S, . Pre-existent left atrial scarring in patients undergoing pulmonary vein antrum isolation: an independent predictor of procedural failure. J Am Coll Cardiol. 2005;45:285–92.
   PubMed Web of Science ®Google Scholar
• Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation. 1995;92: 1954–68.
   PubMed Web of Science ®Google Scholar
• Disertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L, Maggioni AP, . Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med. 2009;360:1606–17.
   PubMed Web of Science ®Google Scholar
• Shroff SC, Ryu K, Martovitz NL, Hoit BD, Stambler BS. Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure. J Cardiovasc Electrophysiol. 2006;17:534–41.
   PubMed Web of Science ®Google Scholar
• Halonen J, Halonen P, Jarvinen O, Taskinen P, Auvinen T, Tarkka M, . Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a randomized controlled trial. JAMA. 2007;297:1562–7.
   PubMed Web of Science ®Google Scholar
• Pellman J, Lyon RC, Sheikh F. Extracellular matrix remodeling in atrial fibrosis: mechanisms and implications in atrial fibrillation. J Mol Cell Cardiol. 2010;48:461–7.
   Google Scholar
• Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74:1141–8.
   PubMed Web of Science ®Google Scholar
• Goette A, Bukowska A, Dobrev D, Pfeiffenberger J, Morawietz H, Strugala D, . Acute atrial tachyarrhythmia induces angiotensin II type 1 receptor-mediated oxidative stress and microvascular flow abnormalities in the ventricles. Eur Heart J. 2009;30:1411–20.
   Google Scholar
• Ehrlich JR, Hohnloser SH, Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J. 2006; 27:512–8.
   PubMed Web of Science ®Google Scholar
• Sun Y, Ramires FJ, Weber KT. Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. Cardiovasc Res. 1997;35:138–47.
   PubMed Web of Science ®Google Scholar
• Burstein B, Nattel S. Atrial structural remodeling as an antiarrhythmic target. J CardiovascPharmacol. 2008; 52:4–10.
   Google Scholar
• L'Allier PL, Ducharme A, Keller PF, Yu H, Guertin MC, Tardif JC. Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. J Am Coll Cardiol. 2004; 44:159–64.
   Google Scholar
• Madrid AH, Bueno MG, Rebollo JM, Marin I, Pena G, Bernal E, . Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation. 2002; 106:331–6.
   PubMed Web of Science ®Google Scholar
• Maggioni AP, Latini R, Carson PE, Singh SN, Barlera S, Glazer R, . Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J. 2005;149:548–57.
   PubMed Web of Science ®Google Scholar
• Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlof B, . Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005;45:712–9.
   PubMed Web of Science ®Google Scholar
• Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, . Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010;12:1360–420.
   PubMed Web of Science ®Google Scholar
• Patel D, Mohanty P, Di Biase L, Wang Y, Shaheen MH, Sanchez JE, . The impact of statins and renin-angiotensin-aldosterone system blockers on pulmonary vein antrum isolation outcomes in post-menopausal females. Europace. 2010;12:322–30.
   Google Scholar
• Verheule S, Sato T, Everett T 4th, Engle SK, Otten D, Rubart-von der Lohe M, . Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1. Circ Res. 2004;94:1458–65.
   PubMed Web of Science ®Google Scholar
• Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol. 2008;51:802–9.
   PubMed Web of Science ®Google Scholar
• Van Wagoner DR. Oxidative stress and inflammation in atrial fibrillation: role in pathogenesis and potential as a therapeutic target. J Cardiovasc Pharmacol. 2008;52:306–13.
   PubMed Web of Science ®Google Scholar
• Fauchier L, Pierre B, de Labriolle A, Grimard C, Zannad N, Babuty D. Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2008;51:828–35.
   PubMed Web of Science ®Google Scholar
• Shiroshita-Takeshita A, Brundel BJ, Lavoie J, Nattel S. Prednisone prevents atrial fibrillation promotion by atrial tachycardia remodeling in dogs. Cardiovasc Res. 2006;69: 865–75.
   PubMed Web of Science ®Google Scholar
• Shiroshita-Takeshita A, Brundel BJ, Burstein B, Leung TK, Mitamura H, Ogawa S, . Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure. Cardiovasc Res. 2007; 74:75–84.
   PubMed Web of Science ®Google Scholar
• Shiroshita-Takeshita A, Schram G, Lavoie J, Nattel S. Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation. 2004;110:2313–9.
   PubMed Web of Science ®Google Scholar
• Heidt MC, Vician M, Stracke SK, Stadlbauer T, Grebe MT, Boening A, . Beneficial effects of intravenously administered N-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a prospective randomized study. Thorac Cardiovasc Surg. 2009;57: 276–80.
   PubMed Web of Science ®Google Scholar
• Saravanan P, Bridgewater B, West AL, O'Neill SC, Calder PC, Davidson NC. Omega-3 fatty acid supplementation does not reduce risk of atrial fibrillation after coronary artery bypass surgery: a randomized, double-blind, placebo-controlled clinical trial. Circ Arrhythm Electro physiol. 2010;3:46–53.
   PubMed Web of Science ®Google Scholar
• Patel D, Shaheen M, Venkatraman P, Armaganijan L, Sanchez JE, Horton RP, . Omega-3 polyunsaturated fatty acid supplementation reduced atrial fibrillation recurrence after pulmonary vein antrum isolation. Indian Pacing Electrophysiol J. 2009;9:292–8.
   Google Scholar
• Pratt CM, Reiffel JA, Ellenbogen KA, Naccarelli GV, Kowey PR. Efficacy and safety of prescription omega-3-acid ethyl esters for the prevention of recurrent symptomatic atrial fibrillation: a prospective study. Am Heart J. 2009;158:163–9;e1–3.
   Google Scholar
• Macchia A, Varini S, Grancelli H, Nul D, Laffaye N, Ferrante D, . The rationale and design of the FORomegaARD Trial: A randomized, double-blind, placebo-controlled, independent study to test the efficacy of n-3 PUFA for the maintenance of normal sinus rhythm in patients with previous atrial fibrillation. Am Heart J. 2009;157:423–7.
   Google Scholar